EHMT2 and central nervous system cancer: BIX01294, selective inhibitor of G9a/EHMT2, could powerfully mediate autophagy and apoptosis through the mTOR/AMPK/ULK1 pathway in various cancer types, such as gastric, breast, oral squamous carcinoma, glioma, and neuroblastoma [20–22].